SLC28A3 rs7853758 as a new biomarker of tacrolimus elimination and new-onset hypertension in Chinese liver transplantation patients
2017
Aim: The effect of SLC28A3 on tacrolimus disposition and new-onset hypertension (NOHP) after liver transplantation (LT) remains unclear. Methodology & results: A total of 169 patients in two cohorts from the China Liver Transplant Registry database were included. Rs7853758 in recipients’SLC28A3 could predict tacrolimus pharmacokinetics in two sets. The model of donors’ CYP3A5 rs776746 and recipients’ CYP3A4 rs2242480 could predict tacrolimus metabolism at week 1 and the model of donors’ CYP3A5 rs776746, recipients’ CYP3A4 rs2242480, recipients’ SLC28A3 rs7853758 and hemoglobin could predict tacrolimus disposition at weeks 2, 3 and 4. Besides, recipients’ SLC28A3 rs7853758 was a new risk factor of NOHP after LT. Conclusion: Rs7853758 in recipients’ SLC28A3 has a correlation with tacrolimus pharmacokinetics and the risk of NOHP in Chinese LT patients.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
31
References
3
Citations
NaN
KQI